Assembly Biosciences, Inc.

NASDAQ:ASMB

Biotechnology

Healthcare
$22.39 +0.66%

+$0.16 today

Market cap
$458.48M
Beta
1.08
P/E (TTM)
-64.4
EPS (TTM)
-$0.38
52W Low $16.50High $39.71

Volume 0.49M

Average 0.17M

ASMB Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Assembly Biosciences, Inc.NASDAQ: ASMB

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns positive

Q1 FY2026 gross profit was $8.19M, compared with -$5.43M a year earlier. Trailing-twelve-month gross profit was $54.91M.

Context

  • Gross profit amounted to 99.8% of revenue in FY2025, up 3.7 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $8.19M or moves back toward the trailing-twelve-month quarterly average of $13.73M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.19M-80.7% QoQ
Last fiscal yearDec 2025
$72.17M+363.3% YoY
LTMMar 2026
$54.91M+621.8% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+250.7%——
1 year+363.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
72.17M USD
Year-over-year change
+363.3%
4-year CAGR
+84.3%

Gross Profit vs competitors

How ASMB compares with its peers on the latest reported figures

  • ASMB's LTM Mar 2026 gross profit of $54.91M is the 4th highest of the 6 companies compared; the peer median is $68M.
  • Its year-over-year change of +621.8% is the 2nd highest of 5, against a peer median of +71.3%.
  • Gross profit amounts to 77.2% of revenue for ASMB, versus a peer median of 100.0%.
ASMB Competitors Peer median
Gross Profit for ASMB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABUSArbutus Biopharma CorporationLTM Mar 2026$191.41M +1784.1%-29.4%100.0%
VIRVir Biotechnology, Inc.LTM Mar 2026$180.27M +137.1%-61.5%275.2%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$68M +5.5%-11.0%98.3%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$54.91M +621.8%—77.2%
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$0 ———
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$40.76M -72.9%——
Peer median (excluding ASMB) $68M+71.3%-29.4%100.0%

Competitors are the stored peer set for ASMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.25M07.16M28.52M72.3M
Cost of Revenue069.08M48.9M55.93M129K
Gross Profit6.25M(69.08M)(41.74M)(27.41M)72.17M
Gross Margin100.0%—-582.7%-96.1%99.8%
Research & Development68.52M69.98M48.9M55.93M64.81M
Selling, General & Admin28.78M23.93M22.91M18.01M19.61M
Operating Expenses138.94M25.03M22.91M18.01M84.42M
Depreciation & Amortization466K498K450K129K129K
EBITDA(90.58M)(92.52M)(60.75M)(39.72M)(5.99M)
EBITDA Margin-1448.4%—-848.0%-139.3%-8.3%
Operating Income(132.69M)(94.11M)(64.65M)(45.42M)(12.12M)
Operating Margin-2121.7%—-902.5%-159.3%-16.8%
Interest Income302K1.02M3.45M5.57M6M
Interest Expense00000
Other Income / Expenses302K1.02M3.45M5.57M6M
Income Before Tax(132.39M)(93.09M)(61.2M)(39.85M)(6.12M)
Pre-Tax Margin-2116.8%—-854.3%-139.7%-8.5%
Income Tax Expense(2.53M)033K330K0
Net Income(129.86M)(93.09M)(61.23M)(40.18M)(6.12M)
Net Margin-2076.4%—-854.8%-140.9%-8.5%
EPS (Basic)(36.00)(22.82)(13.38)(6.69)(0.55)
EPS (Diluted)(36.00)(22.82)(13.38)(6.69)(0.55)
Weighted Avg Shares3.61M4.03M4.58M6M11.21M
Weighted Avg Shares (Diluted)3.61M4.03M4.58M6M11.21M

Assembly Biosciences, Inc.

NASDAQ:ASMB

Intrinsic Alpha fair value

Locked

Current Price

$22.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.